These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 6338134)

  • 1. [The changes of alpha 2-plasmin inhibitor, and notably urokinase activities in blood measured by synthetic chromogenic substrates S-2444 after urokinase administration].
    Itoh Y; Tsuji K; Tanaka N; Yamada M; Nakanishi M; Ishihara M; Kobayashi M
    Nihon Sanka Fujinka Gakkai Zasshi; 1983 Jan; 35(1):68-76. PubMed ID: 6338134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children].
    Koitabashi Y; Ikoma M; Shibawaka T; Yamaguchi Y; Mio H; Doi K; Meguro T; Yamada K
    Nihon Jinzo Gakkai Shi; 1993 Oct; 35(10):1155-61. PubMed ID: 7505345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serial changes in hemostatic molecular markers after urokinase therapy of acute myocardial infarction].
    Goto S; Kawai Y; Watanabe K; Hori S; Abe S; Handa S; Ikeda Y
    Kokyu To Junkan; 1992 Jan; 40(1):89-95. PubMed ID: 1532665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
    Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
    J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis of increased thrombotic tendency with chromogenic substrates].
    Vinazzer H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):135-41. PubMed ID: 6177594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of plasmin with tranexamic acid and alpha 2 plasmin inhibitor in the plasma and clot.
    Takada A; Ito T; Takada Y
    Thromb Haemost; 1980 Feb; 43(1):20-3. PubMed ID: 6447383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
    Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
    Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of dextran sulfate in urokinase therapy and evaluation of the effects by estimation of plasmin inhibitor, fibrinogenolytic degradation products, and fibrinolytic degradation products.
    Hasegawa H; Nagata H; Yamauchi M; Murakoshi T; Oguma Y; Takei H; Seya T; Murao M
    Jpn Heart J; 1982 May; 23(3):339-47. PubMed ID: 6178853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assay of urokinase activity in plasma with a chromogenic substrate.
    Hayashi S; Yamada K
    Thromb Res; 1981 Jun 1-25; 22(5-6):573-8. PubMed ID: 6171046
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative study of the activity of high and low molecular weight urokinase in the presence of fibrin.
    Samama M; Castel M; Matsuo O; Hoylaerts M; Lijnen HR
    Thromb Haemost; 1982 Feb; 47(1):36-40. PubMed ID: 7041325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective determination of alpha 2-plasmin inhibitor activity in plasma using chromogenic substrate.
    Matsuda T; Ogawara M; Miura R; Seki T; Matsumoto T; Teramura Y; Nakamura K
    Thromb Res; 1984 Feb; 33(4):379-88. PubMed ID: 6200949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Thrombolytic agents].
    Furukawa K
    Nihon Geka Gakkai Zasshi; 1984 Sep; 85(9):1166-9. PubMed ID: 6503980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
    Kawakami K; Takahashi A; Yoshimoto T
    No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy.
    Tomino Y; Miura M; Suga T; Yagame M; Endoh M; Nomoto Y; Sakai H; Itoh K; Ikeda N
    Tokai J Exp Clin Med; 1984 Mar; 9(1):43-7. PubMed ID: 6535301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of the immediate plasmin inhibition assay to secure linearity of the reference curve with the chromogenic substrate S-2251.
    Jespersen J; Gram J; Sidelmann J
    Thromb Haemost; 1984 Apr; 51(2):298. PubMed ID: 6740562
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasmin potency estimates: influence of the substrate used in assay.
    Philo RD; Gaffney PJ
    Thromb Haemost; 1981 Apr; 45(2):107-9. PubMed ID: 6454987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical evaluations of antithrombin III and alpha 2-plasmin inhibitor assay method with chromogenic substrates (S-2238, S-2251 (author's transl)].
    Fukuda C; Iijima K; Nakamura K
    Rinsho Byori; 1981 Feb; 29(2):179-82. PubMed ID: 6453246
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic study of the effect of heparin on the amidase activity of trypsin, plasmin and urokinase.
    Yomtova VM; Stambolieva NA; Blagoev BM
    Thromb Haemost; 1983 Jun; 49(3):199-203. PubMed ID: 6224310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.